Literature DB >> 19423726

Recurrent mutations of the STAT6 DNA binding domain in primary mediastinal B-cell lymphoma.

Olga Ritz1, Chrystelle Guiter, Flavia Castellano, Karola Dorsch, Julia Melzner, Jean-Philippe Jais, Gwendoline Dubois, Philippe Gaulard, Peter Möller, Karen Leroy.   

Abstract

Primary mediastinal B-cell lymphoma (PMBL) is a separate entity of aggressive B-cell lymphoma, characterized by a constitutive activation of janus kinase-signal transducer and activator of transcription (JAK-STAT) signaling pathway, also observed in Hodgkin lymphoma. Although many cancers exhibit constitutive JAK-STAT pathway activation, mutations of STAT genes have not been reported in neoplasms. Here, we show that MedB-1 PMBL-derived and L1236 Hodgkin-derived cell lines and 20 of 55 (36%) PMBL cases harbor heterozygous missense mutations in STAT6 DNA binding domain, whereas no mutation was found in 25 diffuse large B-cell lymphoma samples. In 3 cases, somatic origin was indicated by the absence of the mutations in the nontumoral tissue. The pattern of STAT6 mutations was different from the classical features of somatic hypermutations. The mutant STAT6 proteins showed a decreased DNA binding ability in transfected HEK cells, but no decrease in expression of STAT6 canonical target genes was observed in PMBL cases with a mutated STAT6 gene. Although the oncogenic properties of STAT6 mutant proteins remain to be determined, their recurrent selection in PMBL strongly argues for their involvement in the pathogenesis of this aggressive B-cell lymphoma.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19423726      PMCID: PMC2824656          DOI: 10.1182/blood-2009-03-209759

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  34 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  Hodgkin's lymphoma cell lines are characterized by frequent aberrations on chromosomes 2p and 9p including REL and JAK2.

Authors:  Stefan Joos; Martin Granzow; Heidi Holtgreve-Grez; Reiner Siebert; Lana Harder; José I Martín-Subero; Jürgen Wolf; Martyna Adamowicz; Thomas F E Barth; Peter Lichter; Anna Jauch
Journal:  Int J Cancer       Date:  2003-02-10       Impact factor: 7.396

Review 3.  Mediastinal (thymic) large B-cell lymphoma: where do we stand?

Authors:  Thomas F E Barth; Frank Leithäuser; Stefan Joos; Martin Bentz; Peter Möller
Journal:  Lancet Oncol       Date:  2002-04       Impact factor: 41.316

4.  Gain of chromosome arm 9p is characteristic of primary mediastinal B-cell lymphoma (MBL): comprehensive molecular cytogenetic analysis and presentation of a novel MBL cell line.

Authors:  M Bentz; T F Barth; S Brüderlein; D Bock; M J Schwerer; M Baudis; S Joos; A Viardot; A C Feller; H K Müller-Hermelink; P Lichter; H Döhner; P Möller
Journal:  Genes Chromosomes Cancer       Date:  2001-04       Impact factor: 5.006

5.  Interleukin 13 and interleukin 13 receptor are frequently expressed by Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma.

Authors:  B F Skinnider; A J Elia; R D Gascoyne; L H Trümper; F von Bonin; U Kapp; B Patterson; B E Snow; T W Mak
Journal:  Blood       Date:  2001-01-01       Impact factor: 22.113

6.  Signal transducer and activator of transcription 6 is frequently activated in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma.

Authors:  Brian F Skinnider; Andrew J Elia; Randy D Gascoyne; Bruce Patterson; Lorenz Trumper; Ursula Kapp; Tak W Mak
Journal:  Blood       Date:  2002-01-15       Impact factor: 22.113

7.  Expression of a constitutively active Stat6 in vivo alters lymphocyte homeostasis with distinct effects in T and B cells.

Authors:  Heather A Bruns; Ulrike Schindler; Mark H Kaplan
Journal:  J Immunol       Date:  2003-04-01       Impact factor: 5.422

8.  The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma.

Authors:  Kerry J Savage; Stefano Monti; Jeffery L Kutok; Giorgio Cattoretti; Donna Neuberg; Laurence De Leval; Paul Kurtin; Paola Dal Cin; Christine Ladd; Friedrich Feuerhake; Ricardo C T Aguiar; Sigui Li; Gilles Salles; Francoise Berger; Wen Jing; Geraldine S Pinkus; Thomas Habermann; Riccardo Dalla-Favera; Nancy Lee Harris; Jon C Aster; Todd R Golub; Margaret A Shipp
Journal:  Blood       Date:  2003-08-21       Impact factor: 22.113

9.  Interleukin 4-induced gene 1 is activated in primary mediastinal large B-cell lymphoma.

Authors:  Christiane Copie-Bergman; Marie-Laure Boulland; Catherine Dehoulle; Peter Möller; Jean-Pierre Farcet; Martin J S Dyer; Corinne Haioun; Paul-Henri Roméo; Philippe Gaulard; Karen Leroy
Journal:  Blood       Date:  2002-11-21       Impact factor: 22.113

10.  Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma.

Authors:  Andreas Rosenwald; George Wright; Karen Leroy; Xin Yu; Philippe Gaulard; Randy D Gascoyne; Wing C Chan; Tong Zhao; Corinne Haioun; Timothy C Greiner; Dennis D Weisenburger; James C Lynch; Julie Vose; James O Armitage; Erlend B Smeland; Stein Kvaloy; Harald Holte; Jan Delabie; Elias Campo; Emili Montserrat; Armando Lopez-Guillermo; German Ott; H Konrad Muller-Hermelink; Joseph M Connors; Rita Braziel; Thomas M Grogan; Richard I Fisher; Thomas P Miller; Michael LeBlanc; Michael Chiorazzi; Hong Zhao; Liming Yang; John Powell; Wyndham H Wilson; Elaine S Jaffe; Richard Simon; Richard D Klausner; Louis M Staudt
Journal:  J Exp Med       Date:  2003-09-15       Impact factor: 14.307

View more
  40 in total

Review 1.  Pathogenesis of diffuse large B cell lymphoma.

Authors:  Wing John C Chan
Journal:  Int J Hematol       Date:  2010-06-29       Impact factor: 2.490

Review 2.  Ontogeny, Genetics, Molecular Biology, and Classification of B- and T-Cell Non-Hodgkin Lymphoma.

Authors:  Russell James Hubbard Ryan; Ryan Alan Wilcox
Journal:  Hematol Oncol Clin North Am       Date:  2019-05-18       Impact factor: 3.722

3.  Pervasive mutations of JAK-STAT pathway genes in classical Hodgkin lymphoma.

Authors:  Enrico Tiacci; Erik Ladewig; Gianluca Schiavoni; Alex Penson; Elisabetta Fortini; Valentina Pettirossi; Yuchun Wang; Ariele Rosseto; Alessandra Venanzi; Sofija Vlasevska; Roberta Pacini; Simonetta Piattoni; Alessia Tabarrini; Alessandra Pucciarini; Barbara Bigerna; Alessia Santi; Alessandro M Gianni; Simonetta Viviani; Antonello Cabras; Stefano Ascani; Barbara Crescenzi; Cristina Mecucci; Laura Pasqualucci; Raul Rabadan; Brunangelo Falini
Journal:  Blood       Date:  2018-04-12       Impact factor: 22.113

Review 4.  Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review.

Authors:  Rosalba Camicia; Hans C Winkler; Paul O Hassa
Journal:  Mol Cancer       Date:  2015-12-11       Impact factor: 27.401

5.  Activation of the STAT6 transcription factor in Jurkat T-cells by the herpesvirus saimiri Tip protein.

Authors:  Yuri Kim; Eun-Kyung Kwon; Ju-Hong Jeon; Insuk So; In-Gyu Kim; Myung-Sik Choi; Ik-Sang Kim; Joong-Kook Choi; Jae Ung Jung; Nam-Hyuk Cho
Journal:  J Gen Virol       Date:  2011-10-19       Impact factor: 3.891

6.  Genetic alterations of 9p24 in lymphomas and their impact for cancer (immuno-)therapy.

Authors:  Thomas Menter; Alexandar Tzankov
Journal:  Virchows Arch       Date:  2018-08-21       Impact factor: 4.064

7.  Detection and prognostic value of recurrent exportin 1 mutations in tumor and cell-free circulating DNA of patients with classical Hodgkin lymphoma.

Authors:  Vincent Camus; Aspasia Stamatoullas; Sylvain Mareschal; Pierre-Julien Viailly; Nasrin Sarafan-Vasseur; Elodie Bohers; Sydney Dubois; Jean Michel Picquenot; Philippe Ruminy; Catherine Maingonnat; Philippe Bertrand; Marie Cornic; Valérie Tallon-Simon; Stéphanie Becker; Liana Veresezan; Thierry Frebourg; Pierre Vera; Christian Bastard; Hervé Tilly; Fabrice Jardin
Journal:  Haematologica       Date:  2016-06-13       Impact factor: 9.941

Review 8.  JAK kinase targeting in hematologic malignancies: a sinuous pathway from identification of genetic alterations towards clinical indications.

Authors:  Lorraine Springuel; Jean-Christophe Renauld; Laurent Knoops
Journal:  Haematologica       Date:  2015-10       Impact factor: 9.941

9.  Dichotomy between factors inducing the immunosuppressive enzyme IL-4-induced gene 1 (IL4I1) in B lymphocytes and mononuclear phagocytes.

Authors:  Jeanine Marquet; Fanette Lasoudris; Céline Cousin; Marie-Line Puiffe; Nadine Martin-Garcia; Véronique Baud; Fanny Chereau; Jean-Pierre Farcet; Valérie Molinier-Frenkel; Flavia Castellano
Journal:  Eur J Immunol       Date:  2010-09       Impact factor: 5.532

10.  CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study.

Authors:  Shimin Hu; Zijun Y Xu-Monette; Aarthi Balasubramanyam; Ganiraju C Manyam; Carlo Visco; Alexander Tzankov; Wei-min Liu; Roberto N Miranda; Li Zhang; Santiago Montes-Moreno; Karen Dybkær; April Chiu; Attilio Orazi; Youli Zu; Govind Bhagat; Kristy L Richards; Eric D Hsi; William W L Choi; J Han van Krieken; Qin Huang; Jooryung Huh; Weiyun Ai; Maurilio Ponzoni; Andrés J M Ferreri; Xiaoying Zhao; Jane N Winter; Mingzhi Zhang; Ling Li; Michael B Møller; Miguel A Piris; Yong Li; Ronald S Go; Lin Wu; L Jeffrey Medeiros; Ken H Young
Journal:  Blood       Date:  2013-01-23       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.